Understanding how some leukaemia cells survive treatment and cause a relapse
Understanding and therapeutically exploiting clonal evolution in chemo-resistant acute lymphoblastic leukaemia
A new way of treating poor prognosis Wilms’ tumour
Targeting gain of function p53 in poor prognosis Wilms' tumour via histone methyltransferase inhibition
Understanding the biology of relapsed ependymoma brain tumours to help improve treatments
Deciphering the New Molecular Landscape in Paediatric Recurrent Ependymoma: Implications for Molecular Targeted Therapy
Next generation molecular profiling of malignant rhabdoid tumours
Identifying which are the cellular molecules that drive growth and spread of rhabdoid tumours, and to use this information to nominate new treatment strategies and develop real-time diagnostic tests for personalising treatment
Investigating novel drug combinations for acute myeloid leukaemia
Identifying Combination Therapies Targeting Apoptosis pathways in Paediatric AML (CAuSAL study)
Improving the outlook for children with Philadelphia positive ALL
Unravelling clinical heterogeneity in Philadelphia positive ALL
Using repurposed drugs to repair the damage that causes acute myeloid leukaemia
Targeting mutant NRAS in paediatric AML
Mapping drug targets in aggressive non-Hodgkin lymphoma
Investigation of potential therapeutic targets in paediatric aggressive B-cell non-Hodgkin lymphoma - towards kinder, more effective treatments
Can we prevent leukaemia in children?
Modelling prophylactic (microbial) prevention of childhood acute lymphoblastic leukaemia